Drugs / GI-108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07172802 | Apr 2025 → Feb 2027 expected | head and neck squamous cell carcinoma, malignant pancreatic neoplasm, metastatic neoplasm, non-small cell lung carcinoma +1 | GI Innovation, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-14 | GI Innovation, Inc. | Results [보도자료]지아이이노베이션, 4세대 대사면역항암제 GI-108 국제 저명 학술지 JITC 게재 gi-innovation.com ↗
논문에 따르면, 종양미세환경을 모사한 실험 모델에서 GI-108은 경쟁 약물인 아스트라제네카의 올레클루맙 대비 약 8.6배 높은 CD8+ T 세포 활성능을 보였다. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-19 | GI Innovation, Inc. | [보도자료]지아이이노베이션, 면역항암제 ‘GI-108’ 미국 물질특허 등록결정…글로벌 권리 확보 및 임상 본격화 gi-innovation.com ↗ |
| 2025-03-14 | GI Innovation, Inc. | [보도자료]지아이이노베이션, 4세대 대사면역항암제 GI-108 국제 저명 학술지 JITC 게재 gi-innovation.com ↗ |
| 2025-03-06 | GI Innovation, Inc. | [보도자료]지아이이노베이션, 4세대 대사면역항암제 GI-108 임상 개시…”전임상 완전 관해” gi-innovation.com ↗ |
| 2022-10-20 | GI Innovation, Inc. | [보도자료]지아이이노베이션, ‘대사면역항암제 GI-108’ 국가신약개발사업 비임상 지원 과제 선정 gi-innovation.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GI-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07172802 ↗ |
| Modality | Protein / enzyme biologic | “Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein” NCT07172802 ↗ |
| Route | Intravenous | “administered via IV infusion” NCT07172802 ↗ |